Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
Guggenheim Initiates Rhythm Pharmaceuticals(RYTM.US) With Buy Rating, Announces Target Price $70
Express News | Rhythm Pharmaceuticals Inc : Guggenheim Initiates Coverage With Buy Rating; Target Price $70
Rhythm Pharmaceuticals Is Maintained at Neutral by B of A Securities
BofA Securities Maintains Rhythm Pharmaceuticals(RYTM.US) With Hold Rating, Raises Target Price to $52